Clinical Trials of Antiarrhythmic Drugs in Postmyocardial Infarction and Congestive Heart Failure Patients

Abstract

References

1. Myerburg RJ , Kessler KM , Castellanos. Sudden cardiac death. Structure, function, and time-dependent of risk. Circulation 85(Suppl I):12-110, 1992

2. Echt DS , Liebson PR , Mitchell LB , Peters RW , ObiasManno D , Barker AH , et al. Mortality and morbidity in patients receiving encanide, fleccanide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-787, 1991

3. The Cardiac Arrhythmia Suppression Trial II Investigators . Effect of the anti-arrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227-233, 1992

4. Teo KK , Yusuf S , Furberg CD . Effects of propylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomised trials. JAMA 270:1589-1595, 1993

5. Yusuf S , Peto R , Lewis J , et al. Beta Blockade during and after myocardial infarction: an overview of the randomised trials. Prog cardiovasc Dis 27:335-371, 1985

6. The Beta-blocker Pooling Project Research Group . The beta-blocker pooling project (BBPP): subgroup findings from randomised trials in post infarction patients. Eur Heart J 9:8-16, 1988

7. Beta-blocker Heart Attack Trial Research Group . A randomised trial of propranolol in patients with acute myocardial infarction I. Marketed results. JAMA 247:1707-1714, 1982

8. Beta-blocker Heart Attack Trial Research Group . A randomised trial of propranolol in patients with acute myocardial infarction II. Morbidity results. JAMA 250:2814-2819, 1983

9. The Norwegian Multicenter Study Group . Timololinduced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801-807, 1981

10.

10. Olsson G , Rehnqvist N , Sjogren A , et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardial 5:1428-1437, 1985

11.

11. Boissel J-P , Leizorovicz A , Picolet H , Peyrieux J-C . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutalol. Am J Cardiol 66:251-260, 1990

12.

12. First Intemational Study of Infarct Survival Collaborative Group . Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2:57-66, 1986

13.

13. The TIMI Study Group . Collaborative of invasive and consecutive strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 320:618-627, 1989

14.

14. Olsson G , Oden A , Ansson L , et al. Prognosis after withdrawal of chronic postinfarction metoprolol tretament: a 2-7 year follow-up. Eur Heart J 9:365-372, 1988

15.

15. Pedersen TR for the Norwegian Multicenter Study Group . Six-year follow-up of the Norwegian Multicenter Study on timolol after acute myocardial infarction. New Engl J Med 313:1055-1059, 1985

16.

16. Ryan TJ , Anderson JL , Antman EM , et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 28:1328-1428, 1996

17.

17. Julian DG , Prescott RJ , Jackson FS , Szekely P . Controlled trial of sotalol for one year after myocardial infarction. Lancet I: 1142-1147, 1982

18.

18. Waldo AL , Camm AJ , deRuyter H , Friedman PL , MacNeil DJ , Pauls JF , Pitt B , Pratt CM , Schwartz PJ , Veitri EP , for the SWORD investigators . Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348:7-12, 1996

19.

19. Cairns JA , Connolly SJ , Roberts R , Gent M , for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial investigators. The Lancet 349:675-682, 1997

20.

20. Julian D , Camm AJ , Frangin G , Janse MJ , Munoz A , Schwartz PJ , Simon P , for the European Myocardial Infarct Amiodarone Trial Investigators. The Lancet 349:667-674, 1997

21.

21. Amiodarone Trials Meta-Analysis Investigators .Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6,500 patients in randomised trials. Lancet 350:1417-1424, 1997

22.

22. Sim I , McDonald KM , Lavori PW , Norbutas CM , Hlatky MA . Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 96: 2823-2829, 1997

23.

23. Bashir Y , Thomsen P-E B , Kingma JH , Moller M , Wong C , Cobbe S , Jordaens L , Campbell RWF , Rasmussen HS , Camm AJ . Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 76:1040-1044, 1995

24.

24. The DIAMOND Study Group . Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patients characteristics of the DIAMOND studies. Clin Cardiol 20:704-710, 1997

25.

25. Danish Trial in Acute Myocardial Infarction on Dofetilide (DIAMOND). Preliminary results presented at the European Congress of Cardiology. Stockholm, August, 1997

26.

26. Waagstein F , Bristow MR , Swedberg K , Camerini F , Fowler MB , Silver MA , Gilbert EM , Johnson MR , Goss FG , Hjalmarson A . Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyoapthy (MDC) Trial Study Group. Lancet 342:1441-1446,1993

27.

27. Di Lenarda A , De Maria R , Gavazzi A , Gregori D , Parolini M , Sinagra G , Salvatore L , Longaro F , Bernobich E , Camerini F . Long-term survival effect of metoprolol in dilated cardiomyopathy. The SPIC (Italian Multicentre Cardiomyopathy Study) Group. Heart 79:337-344, 1998

28.

28. Effects of metoprolol CRIXL in chronic heart failure : Metoprolol CRIXL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2001, 1999

29.

29. Colucci WS , Packer M , Bristow MR , Gilbert EM , Cohn JN , Fowler MB , Krueger SK , Hershberger R , Uretsky BF , Bowers JA , Sackner-Bernstein JD , Young ST , Holcslaw TL , Lukas MA . Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94:2800-2806, 1996

30.

30. Packer M , Colucci WS , Sackner-Bernstein JD , Liang CS , Goldscher DA , Freeman I , Kukin ML , Kinhal V , Udelson, JE , Klapholz M , Gottlieb SS , Pearle D , Cody RJ , Gregory JJ , Kantrowitz NE , LeJemtel TH , Young ST , Lukas MA , Shusterman NH . Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 94:2793-2799, 1996

31.

31. Packer M , Bristow MR , Cohn JN , Colucci WS , Fowler MB , Gilbert EM , Shusterman NH . The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med 334:1349-1355, 1996

32.

32. Bristow MR , Gilbert EM , Abraham WT , Adams KF , Fowler MB , Hershberger RE , Kubo SH , Narahara KA , Ingersoll H , Krueger S , Young S , SmYV erman N . Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807-2816, 1996

33.

33. Australia-New Zealand Heart Failure Research Collaborative Group . Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375-380, 1997

34.

34. CIBIS Investigators and Committees . A randomised trial of beta-blockade in heart failure: The Cardiac Insufficiency Blsoprolol Study (CIBIS). Circulation 90:1765-1773, 1994

35.

35. CIBIS-I1 Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13, 1999

36.

36. Doughty RN , Rodgers A , Sharpe N , MacMahon S . Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 18:560-565, 1997

37.

37. Lechat P , Packer M , Chalon S , Cucherat M , Arab T , Boissel JP . Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98:1184-1191, 1998

38.

38. Heidenreich PA , Lee TT , Massie BM . Effect of beta-blockade on mortality in patients with heart failure: a metaanalysis of randomized clinical trials. J Am Coll Cardiol 30:27-34, 0000

39.

39. Teerlink JR , Massie BM . Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 844:94R-102R, 1999

40.

40. The BEST Steering Committee . Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 75:1220-1223, 1995

41.

41. Massie BM , Fisher SG , Radford M , Deedwania PC , Singh BN , Fletcher RD , Singh SN . Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 93:2128-2134, 1996

42.

42. Doval HC , Nul DR , Grancelli HO , Perrone SV , Bortman GR , Ouriel R . Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344:493-498, 1994

43.

43. Doval H . Class III antiarrhythmic agents in cardiac failure: lessons from clinical trials with a focus on the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Am J Cardiol 84:109R-114R, 1999

44.

44. Torp-Pedersen C , Moller M , Bloch-Thomsen PE , Kober L , Sandoe E , Egstrup K , Agner E , Carlsen J , Videbaek J , Marchant B , Camm AJ . Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341:857-865, 1999